Optimizing the timing of JAK1 inhibition preserves the anti-tumor efficacy of radioimmunotherapy in lung cancer by preventing T cell exhaustion
Abstract JAK1 inhibitors are widely used in hematologic malignancies and autoimmune diseases, their potential in combination with immunotherapy for solid tumors such as lung cancer is increasingly being recognized. The combination of radiotherapy and immunotherapy (radioimmunotherapy, iRT) has becom...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2026-07-01
|
| Serier: | Experimental Hematology & Oncology |
| Fag: | |
| Online adgang: | https://doi.org/10.1186/s40164-026-00802-3 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|